Acumen presents poster describing method to standardize amyloid beta oligomer assays supporting therapeutic development for early Alzheimer’s disease
01 août 2022 10h30 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Scientists at Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) have developed a synthetic model to potentially standardize the...
Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer’s Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer’s Disease
29 juil. 2022 07h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., July 29, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Cognition Therapeutics Presenting New Analyses from Ongoing Clinical Trial of CT1812 in Mild-to-Moderate Alzheimer’s Disease
19 juil. 2022 08h00 HE
|
Cognition Therapeutics, Inc.
- Analyses Demonstrate CT1812 Impact on Alzheimer’s Disease Processes - NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) will be in attendance at the 2022...
New Alzheimer's Treatment on Horizon as Dementia Reversed for First Time in Dogs
21 juin 2022 07h46 HE
|
Skin2Neuron Pty Ltd.
SYDNEY, June 21, 2022 (GLOBE NEWSWIRE) -- With the once dominant amyloid hypothesis of Alzheimer's disease suffering yet another crushing blow this week, the field is desperate for a ray of hope....
Neurodegenerative Diseases Market to reach USD 53 Billion by 2030 and grow steadily at a CAGR of 3.2%: Straits Research
27 mai 2022 11h30 HE
|
Straits Research
New York, United States, May 27, 2022 (GLOBE NEWSWIRE) -- Neurodegenerative diseases are a large and diverse group of disorders characterized by progressive deterioration of the function and...
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET
25 mai 2022 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., May 25, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update
16 mai 2022 08h15 HE
|
Vaccinex, Inc.
Excellent Progress in Pepinemab Clinical Programs Promising responses in Phase 1b segment of the open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck...
Comprehensive Analysis in Frontiers in Neuroscience Highlights Acumen Pharmaceuticals’ New Approach to Treating Alzheimer's Disease
27 avr. 2022 08h00 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., April 27, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel...
Alzheimer’s Therapeutics Market Is Set to Expand at a CAGR Of 9.3% To reach US$ 6.8 Bn By The Year 2032 : FMI
15 avr. 2022 08h00 HE
|
Future Market Insights Global and Consulting Pvt. Ltd.
DUBAI, United Arab Emirates, April 15, 2022 (GLOBE NEWSWIRE) -- Alzheimer’s Therapeutics is the most common reason for progressive dementia in the elderly population. There has been an exponential...
Neuronascent Releases Further Positive Results of NNI-362 in A Randomized Phase 1a Trial for Alzheimer’s Disease
30 mars 2022 06h00 HE
|
Neuronascent, Inc.
ROCKVILLE, Md., March 30, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc., is a clinical-stage pharmaceutical company discovering and developing novel regenerative therapies for age-related brain...